Story perspectives

Hims & Hers Soars 60% Amid Novo Nordisk Partnership

5/5/2025

25 4

Summary

Story summary

Hims & Hers Health (NYSE: HIMS) has surged 60% YTD, fueled by a partnership with Novo Nordisk for Wegovy®.
Revenue estimates for Q1 2025 stand at $537.85 million, with projections of $2.3-$2.4 billion for the year.
The company reported $1.5 billion in revenue for 2024, a 69% increase and its first full-year GAAP profitability.
Analysts have mixed views on HIMS's valuation, with some raising price targets while others cite high P/E ratios and competition concerns.

1 of 1

Story summary

Hims & Hers Health (NYSE: HIMS) has surged 60% YTD, fueled by a partnership with Novo Nordisk for Wegovy®.
Revenue estimates for Q1 2025 stand at $537.85 million, with projections of $2.3-$2.4 billion for the year.
The company reported $1.5 billion in revenue for 2024, a 69% increase and its first full-year GAAP profitability.
Analysts have mixed views on HIMS's valuation, with some raising price targets while others cite high P/E ratios and competition concerns.